ScreenerHero

QNRX Quoin Pharmaceuticals, Ltd.

NAS · US · Healthcare · Biotechnology · quoinpharma.com
4.700USD-0.42%Mkt Cap: 22.58M $P/E: —

Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead p…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap22.58M USD
Enterprise Value703.38K USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-15.80M USD
Revenue/Share—
Last Price4.700 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.48
PEG—
EV/EBITDA-0.04
EV/Revenue—
P/S—
P/B0.54
EPS (TTM)-5.67
EPS (Forward)-3.19
52W Range
3.2504% of range41.80
52W High41.80 USD
52W Low3.250 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-120.46%
ROA-77.51%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.54M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-35.43%
Net Debt-8.78M USD
Net Debt/EBITDA0.46
Balance Sheet
Debt/Equity51.46
Current Ratio1.76
Quick Ratio1.63
Book Value/Sh8.76 USD
Cash/Share5.38 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateOct 23, 2019
Splits
Last Split1:35
Split DateApr 9, 2025
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)21.83 USD
Upside (mean)+364.5%
Target Range12.00 USD – 35.00 USD
12.00+364.5% to mean35.00
# Analysts6
Ownership
Shares Out.4.80M
Float1.93M
Insiders3.67%
Institutions27.75%
Short Interest
Short Ratio0.1d
Short % Float6.31%
Short % Out.6.29%
Shares Short126.29K
Short (prev mo.)111.30K
Technical
SMA 505.665 (-17.0%)
SMA 2006.928 (-32.2%)
Beta1.75
S&P 52W Chg15.78%
Avg Vol (30d)1.11M
Avg Vol (10d)45.13K
Technical Indicators
RSI (14)37.4
MACD-0.3486
MACD Signal-0.0993
MACD Hist.-0.2492
BB Upper8.213 USD
BB Middle6.012 USD
BB Lower3.812 USD
BB Width73.21%
ATR (14)0.5433 USD
Vol Ratio (20d)0.32x